Core Viewpoint - The pharmaceutical sector has experienced a slowdown in momentum after a strong rally earlier in the year, with a significant reduction in the number of "doubling funds" [1][2]. Group 1: Market Performance - As of November 28, only two pharmaceutical-themed funds, Bank of China Hong Kong Stock Connect Pharmaceutical A and Chuangjin Hexin Global Pharmaceutical Biotechnology A, maintained over 100% returns for the year, with cumulative returns of 107.69% and 100.32% respectively [2]. - The average return of pharmaceutical-themed funds has retreated by approximately 10% from the peak in September [2]. - Major pharmaceutical ETFs, including the CSI 300 Healthcare Index and the CSI All Share Healthcare Index, have seen a decline in scale over the past three months, indicating a slowdown in passive fund inflows [2]. Group 2: Policy Environment - The policy environment for the pharmaceutical industry is expected to remain positive, with three key factors identified: clear top-level design, scientific regulation, and standardized development of traditional Chinese medicine [3][4]. - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, providing comprehensive support across various stages [3]. - The upcoming negotiations for the national basic medical insurance directory and commercial insurance innovative drug directory are anticipated to enhance funding sources for the healthcare industry [3][4]. Group 3: Valuation and Investment Outlook - The pharmaceutical industry has been ranked relatively low in terms of valuation over the past four years, indicating that it has undergone sufficient valuation digestion, suggesting potential upside [6]. - The industry is transitioning from a "short-term trading" mindset to a focus on "valuation recovery," with signs of performance improvement following the release of Q3 reports [6]. - The Federal Reserve's interest rate cuts are expected to facilitate a recovery in pharmaceutical investment and financing, further strengthening the positive outlook for the industry [7].

Market Overview - A-shares indices collectively strengthened, with the Shanghai Composite Index making another push towards 3500 points, closing up 0.7%, Shenzhen Component up 1.46%, and ChiNext up 2.39% [1] - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.4 trillion yuan [1] Sector Performance - The power-related ETFs led the gains, with multiple solar energy ETFs rising over 5% [2] - The recent "anti-involution" discourse in the solar industry has been highlighted, with government meetings emphasizing the need to address low-price competition and promote product quality [2][3] Industry Insights - Pacific Securities noted that the government's stance on "anti-involution" signals a potential acceleration in supply-side capacity clearing and may drive technological breakthroughs in the solar industry, indicating a possible turning point [3] - The solar industry is expected to shift from price wars to technological differentiation, optimizing capacity structure and accelerating technological progress, which will drive equipment demand [3] Pharmaceutical Sector - The pharmaceutical sector is experiencing a pullback, but Huachuang Securities remains optimistic about the industry's growth in 2025, citing low valuations and favorable macroeconomic factors [4] - The focus is shifting from quantity to quality in the domestic innovative drug sector, with an emphasis on products that can deliver profits [4] ETF Activity - The Hong Kong Securities ETF (513090) showed significant trading activity, with a trading volume exceeding 15.7 billion yuan [5] - The turnover rate for the benchmark government bond ETF (511100) reached 415.24%, indicating high trading activity [6] - The Hong Kong Securities ETF is designed for investors with a higher risk tolerance, particularly in times of policy benefits or improved market liquidity [6]

证券研究报告|医药生物|2025年3月29日 www.hczq.com 华创医药投资观点&研究专题周周谈·第119期 2025Q1医药业绩前瞻 本报告由华创证券有限责任公司编制 报告仅供华创证券有限责任公司的客户使用，本公司不会因按久收到本报告而预其为客户。华创证券的这些信息的准确性和完整性不作任何保证，报告中的内容和赏见仅体参考，并不构成本公司对所述证券买 卖的出价或狗价，本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 :请仔细阅读PPT后部分的分析师声明及免责声明。 ER | 01 | 行情回顾 | | --- | --- | | 02 | 板块观点和投资组合 | | 03 | 行业和个股事件 | 本周行情回顾 = 华创研究 本周中信一级行业指数涨跌幅 09 -1% -25 -3% -4% -5% -69 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号: S0360520110002 邮箱: zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.co ...